Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[Cu2(sal-D,L-glu)2(isoquinoline)2] is a binuclear Schiff base copper(II) complex investigated for its potential as an anticancer agent. The complex consists of copper ions coordinated with N-salicylidene-D,L-glutamate and isoquinoline ligands. It functions as a proteasome inhibitor, specifically targeting the ubiquitin-proteasome pathway to induce apoptosis in tumor cells. Research has demonstrated its cytotoxic activity against various human cancer cell lines, including A549 lung carcinoma, HeLa cervix carcinoma, and U-118MG glioblastoma cells. By inhibiting proteasome activity, the complex leads to the accumulation of ubiquitinated proteins, triggering programmed cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [Cu2(sal-D,L-glu)2(isoquinoline)2].